Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age.
Phase of Trial: Phase II
Latest Information Update: 16 Dec 2016
At a glance
- Drugs Gefitinib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 30 Nov 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 30 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.